An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, according to a poster presented here. This molecular characterization may ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that ...

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform TM provides ...

Serina Therapeutics (SER) announced that Randall Moreadith, CDO, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

There have been hundreds of measles cases reported in the U.S. since the beginning of the year. Here's what you need to know ...

Type I allergy, an IgE antibody triggered hypersensitivity disease, represents a common public health problem affecting about one third of the world´s population. Upon exposure to allergens, IgE ...

Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in ...

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...

HER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...